SCHEMBL13877449

SCHEMBL13877449

c1cc(-c2nc(-n3c4ccccc4c4ccccc43)c3ccccc3n2)cc(-c2nc(-n3c4ccccc4c4ccccc43)c3ccccc3n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.51
ABCG2 Q9UNQ0 4/20 0.49
TSHR P16473 6/20 0.47
CYP1A2 P05177 5/20 0.47
CYP3A4 P08684 5/20 0.47
CYP2D6 P10635 4/20 0.47
MAPK1 P28482 4/20 0.47
LMNA P02545 3/20 0.47
USP2 O75604 3/20 0.47
TP53 P04637 2/20 0.47
CLK4 Q9HAZ1 1/20 0.47
MAPT P10636 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 2/20 0.44
ACHE P22303 1/20 0.44
NR1I3 Q14994 2/20 0.43
VDR P11473 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13877273 0.92 ACP1 (0.50) ACP1ABCG2TSHRCYP1A2CYP3A4
SCHEMBL13877271 0.92 ACP1 (0.59) ACP1ABCG2TSHRMAPK1LMNA
SCHEMBL15213846 0.85 ACP1 (0.50) ACP1ABCG2TSHRCYP1A2CYP3A4
SCHEMBL17904246 0.85 ABCG2 (0.45) ACP1ABCG2TSHRCYP1A2CYP3A4
SCHEMBL17878986 0.85 ABCG2 (0.45) ACP1ABCG2TSHRCYP1A2CYP3A4
SCHEMBL18213925 0.85 ABCG2 (0.45) ACP1ABCG2TSHRCYP1A2CYP3A4
SCHEMBL20226349 0.85 ACP1 (0.41) ACP1ABCG2TSHRCYP1A2CYP3A4
SCHEMBL22175034 0.85 ABCG2 (0.48) ACP1ABCG2TSHRMAPK1LMNA
SCHEMBL15371685 0.84 ABCG2 (0.50) ACP1ABCG2TSHRMAPK1LMNA
SCHEMBL26598439 0.84 ABCG2 (0.53) ACP1ABCG2TSHRMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090091240-A1 COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2009-04-09 US disclosed
US-20090091240-A1 COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2009-04-09 US disclosed
EP-1808433-A1 COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME IDEMITSU KOSAN COMPANY LIMITED (JP) 2007-07-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090091240-A1 COMPOUND CONTAINING FUSED RING AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME INTS9, KCNN2, KCNH3 ACP1 3070/4885ABCG2 922/4885TSHR 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.